Molecular predictors of response to panobinostat in DLBCL. The presence of molecular biomarkers before therapy and after only 15 days of treatment predicted response in patients with relapsed DLBCL, and transformed lymphomas treated with panobinostat. The presence of a mutation in the histone-modifying enzyme MEF2B prior to therapy, increased the likelihood of response by almost fourfold, whereas levels of ctDNA in the plasma at day 15 was a strong predictor of response. Virtually all patients who responded to panobinostat (light green line) saw an immediate reduction in ctDNA levels by day 15, whereas patients refractory to therapy (dark green line) had an increase in ctDNA. Other patients only partially responded with ctDNA (red line), but did not have a clinical response. Professional illustration by Somersault18:24.